Pearls & Oy-sters: CNS lymphoma in a patient with relapsing-remitting multiple sclerosis treated with interferon.
作者信息
Chiang Sharon, Kesari Navin K, Bradshaw Anthony, Chen Wendy, Samudralwar Rohini, Alobaidy Ammar M, Kass Joseph S
机构信息
From the School of Medicine (S.C.) and Department of Neurology (N.K.K., A.B., W.C., R.S., A.M.A., J.S.K.), Baylor College of Medicine, Houston, TX.
出版信息
Neurology. 2017 Oct 24;89(17):e210-e213. doi: 10.1212/WNL.0000000000004579.
Abstract
摘要
相似文献
1
Pearls & Oy-sters: CNS lymphoma in a patient with relapsing-remitting multiple sclerosis treated with interferon.经验与教训：1例复发缓解型多发性硬化患者接受干扰素治疗后发生中枢神经系统淋巴瘤
Neurology. 2017 Oct 24;89(17):e210-e213. doi: 10.1212/WNL.0000000000004579.
2
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.奥扎莫德与干扰素β-1a 在复发型多发性硬化症中的安全性和疗效（SUNBEAM）：一项多中心、随机、至少 12 个月、3 期临床试验。
Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3.
3
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.奥扎莫德与干扰素β-1a 在复发型多发性硬化症（RADIANCE）中的安全性和疗效：一项多中心、随机、24 个月、3 期临床试验。
Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3.
4
Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.皮下注射干扰素β-1a每周三次对复发缓解型多发性硬化症患者1年时临床和影像学指标及无疾病活动证据状态的影响。
BMC Neurol. 2018 Sep 14;18(1):143. doi: 10.1186/s12883-018-1145-x.
5
Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.奥瑞珠单抗与皮下注射干扰素β-1a治疗复发型多发性硬化症的成本效益分析。
J Med Econ. 2017 Oct;20(10):1056-1065. doi: 10.1080/13696998.2017.1355310. Epub 2017 Jul 31.
6
Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis - A case report.一名多发性硬化症患者接受β-干扰素治疗后发生横纹肌溶解症——病例报告
Mult Scler Relat Disord. 2016 Jul;8:93-5. doi: 10.1016/j.msard.2016.05.005. Epub 2016 May 16.
7
Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.达克珠单抗与干扰素β-1a对复发缓解型多发性硬化症患者报告结局的影响。
Mult Scler Relat Disord. 2017 Jan;11:18-24. doi: 10.1016/j.msard.2016.11.005. Epub 2016 Nov 13.
8
Relationship between Interferon Beta-1A Administration and Intracranial Vascular Tone Regulation in Patients with Relapsing-Remitting Multiple Sclerosis: A Pilot Study.干扰素 β-1A 给药与复发缓解型多发性硬化患者颅内血管张力调节的关系：一项初步研究。
Biomed Res Int. 2017;2017:5421416. doi: 10.1155/2017/5421416. Epub 2017 Sep 13.
9
Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.肌内注射干扰素β-1a 的长期疗效和安全性：两种剂量方案在日本复发缓解型多发性硬化症患者中的随机上市后试验。
Mult Scler Relat Disord. 2016 May;7:102-8. doi: 10.1016/j.msard.2016.02.002. Epub 2016 Feb 2.
10
Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.聚乙二醇干扰素 β-1a 治疗复发缓解型多发性硬化症（ADVANCE）：一项随机、3 期、双盲研究。
Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30.
引用本文的文献
1
Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports.醋酸格拉替雷和干扰素β-1a治疗多发性硬化症患者的不良副作用：病例报告的系统评价
Curr J Neurol. 2023 Apr 4;22(2):115-136. doi: 10.18502/cjn.v22i2.13340.
本文引用的文献
1
The development of primary central nervous system B-cell lymphoma in multiple sclerosis.多发性硬化症中原发性中枢神经系统B细胞淋巴瘤的发展
Neurohospitalist. 2011 Jul;1(3):133-6. doi: 10.1177/1941875211401751.
2
Effect of interferon beta-1a on B7.1 and B7.2 B-cell expression and its impact on T-cell proliferation.干扰素 beta-1a 对 B7.1 和 B7.2 B 细胞表达的影响及其对 T 细胞增殖的影响。
J Neuroimmunol. 2013 May 15;258(1-2):27-31. doi: 10.1016/j.jneuroim.2013.02.010. Epub 2013 Mar 13.
3
The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings.多发性硬化症患者接受皮下注射干扰素β-la 治疗不会增加恶性肿瘤风险：临床试验和上市后监测数据的分析。
Mult Scler. 2011 Apr;17(4):431-40. doi: 10.1177/1352458511403642.
4
Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid.多发性硬化症：脑脊液中的 BAFF 和 CXCL13。
Mult Scler. 2011 Jul;17(7):819-29. doi: 10.1177/1352458511398887. Epub 2011 Mar 3.
5
Central nervous system lymphoma: characteristic findings on traditional and advanced imaging.中枢神经系统淋巴瘤：传统和先进成像技术的特征表现。
AJNR Am J Neuroradiol. 2011 Jun-Jul;32(6):984-92. doi: 10.3174/ajnr.A2171. Epub 2010 Jul 8.
6
Epstein Barr virus-associated primary CNS lymphomas in elderly patients on immunosuppressive medications.接受免疫抑制药物治疗的老年患者中的爱泼斯坦-巴尔病毒相关原发性中枢神经系统淋巴瘤
J Neuropathol Exp Neurol. 2008 Nov;67(11):1103-11. doi: 10.1097/NEN.0b013e31818beaea.
7
Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis.病理确诊的肿胀型多发性硬化症的临床和影像学表现谱
Brain. 2008 Jul;131(Pt 7):1759-75. doi: 10.1093/brain/awn098. Epub 2008 Jun 5.
8
Multiple sclerosis preceding CNS lymphoma: a case report.
Acta Neurol Taiwan. 2007 Jun;16(2):92-7.
9
IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis.白细胞介素-15在多发性硬化症患者的血清和脑脊液中水平升高。
J Neurol Sci. 2006 Feb 15;241(1-2):25-9. doi: 10.1016/j.jns.2005.10.003. Epub 2005 Nov 28.
10
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma.B淋巴细胞刺激因子由星形胶质细胞产生，在多发性硬化症病变和原发性中枢神经系统淋巴瘤中上调。
J Exp Med. 2005 Jan 17;201(2):195-200. doi: 10.1084/jem.20041674. Epub 2005 Jan 10.
Zotero 插件